GYRE Projected Dividend Yield
Gyre Therapeutics Inc ( NASDAQ : GYRE )Gyre Therapeutics, Inc. is a clinical-stage biotechnology company. Co. is engaged in the research, development, manufacturing, and commercialization of drugs for organ fibrosis. It is primarily focused on the development and commercialization of F351 (Hydronidone) for the treatment of Nonalcoholic Steatohepatitis Treatment (NASH)-associated fibrosis. Co. is also advancing a diverse pipeline in the China through its indirect controlling interest in Gyre Pharmaceuticals, including ETUARY therapeutic expansions, F573, F528, and F230. Co. operates through two segments: Gyre Pharmaceuticals, and Gyre after the Contributions. 20 YEAR PERFORMANCE RESULTS |
GYRE Dividend History Detail GYRE Dividend News GYRE Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |